BAYER AG NA O.N.
Commented by André Will-Laudien on May 21st, 2026 | 07:10 CEST
Undervalued – Analysts Turn Their Attention to Life Sciences: Bayer, Vidac Pharma, Novo Nordisk, and Pfizer in Focus
DZ Bank's aggressive price target adjustment for Bayer demonstrates that analysts have recently begun to view the life sciences sector more favourably. The pharmaceutical and agrochemical group's strong start to the year has led to significantly improved prospects, and legal risks are now also viewed as more moderate. Finally, some good news for long-suffering investors in a geopolitically volatile environment. After all, there have not been any major upgrades in the sector for quite some time. When it comes to Novo Nordisk, however, experts remain divided on whether the earnings trend will turn positive again. Cutthroat competition in the weight-loss drug market is intense, putting pressure on margins. Buoyed by industry sentiment, Pfizer also saw its stock rise again. Time for a new tour of the sector. Where are the triggers?
Read
Commented by Matthias Schomber on May 14th, 2026 | 07:55 CEST
Bayer and BASF on a Performance High — and MustGrow Biologics as a Secret Weapon Against World Hunger!
Created and published on behalf of MustGrow Biologics Corp.
The world's population is growing inexorably, and with it the demand for efficient—but above all sustainable—solutions in agriculture. While the German heavyweights Bayer and BASF have recently impressed markets with strong performance and further cemented their dominant positions, a smaller player is preparing to emerge from the slipstream of the industry giants and join the major leagues. Hardly anyone is likely to have this stock on their radar yet, but it would be worth at least adding it to the watchlist. MustGrow Biologics may have endured a difficult stretch on the stock market, but recent strategic decisions and regulatory successes suggest that the company could be delivering the right answers to pressing global food security challenges at exactly the right time. The market currently appears to be bottoming out, which could mark an attractive entry point for risk-tolerant investors before the biological agriculture trend gains further momentum. In this report, we examine the latest developments at these three companies in the battle for the farmland of the future.
Read
Commented by Nico Popp on May 14th, 2026 | 07:50 CEST
Checkmate for Cancer: What Eli Lilly and Bayer Can Learn from Vidac Pharma
Modern medicine is on the cusp of groundbreaking innovations in which the regulation of cellular energy metabolism, known as metabolic correction, is becoming a decisive strategy. While traditional cancer research has relied primarily on the destruction of cells using toxic agents for decades, researchers now recognize that the key to success may lie in the precise control of enzymatic processes. In light of this, value creation is shifting away from the conventional "sledgehammer approach" toward correcting cellular dysregulation. We highlight three exciting companies and focus in particular on metabolism pioneer Vidac Pharma.
Read
Commented by Fabian Lorenz on May 13th, 2026 | 07:30 CEST
Takeover at Bayer! Shock at Rheinmetall! Opportunity for MustGrow Stock!
Created and published on behalf of MustGrow Biologics Corp.
The blockade of the Strait of Hormuz is turning into a stress test for global food security. Supply chains across the fertilizer industry are coming under pressure — and this could create a significant opportunity for MustGrow Biologics. The company's organic biological fertilizer (biofertilizer) is being approved in an increasing number of US states. And in the field of biological crop protection, they are collaborating with Bayer. Meanwhile, Rheinmetall is grappling with disappointed market expectations. Revenues at the defence contractor are simply not growing fast enough, although the company continues to modernize its product portfolio.
Read
Commented by Armin Schulz on May 5th, 2026 | 07:10 CEST
How to Capitalize on Two of the Greatest Crises of Our Time – Thanks to Novo Nordisk, MustGrow Biologics, and Bayer
Created and published on behalf of MustGrow Biologics Corp.
While the world battles an obesity epidemic that has turned Novo Nordisk into a cash cow, a potential conflict with Iran threatens to tear apart global agricultural supply chains. More than 2.5 billion people are overweight, while war-induced fertilizer shortages could destroy crops. Two seemingly contradictory crises collide—pharmaceutical solutions for obesity on one side, biological crop protection products against famine on the other. It is precisely in this tension that three companies, each pursuing different approaches, are operating: Novo Nordisk, MustGrow Biologics, and Bayer.
Read
Commented by Fabian Lorenz on April 30th, 2026 | 07:40 CEST
Buy recommendations for Rheinmetall and Antimony Resources! What is going on at Bayer?
Created and published on behalf of Antimony Resources Corp.
Is Rheinmetall's stock heading back toward EUR 2,000? Maybe even higher? Analysts are convinced of this. Negative scenarios are already priced into the share price. The latest order shows that operations are running smoothly at Germany's largest defence contractor. Strong news from Antimony Resources as well. Drilling results are impressive once again, making analysts' price targets increasingly plausible. They see the stock rising by over 150%. Bayer shares have had a tough time in recent weeks. The glyphosate stress is back. The issue had been sidelined for months, and the stock had been on an upward trajectory. Then, starting in mid-February, came the sharp sell-off. What do analysts say?
Read
Commented by Mario Hose on April 27th, 2026 | 07:55 CEST
Mustard Power as a Growth Turbo! Agricultural Giants vs Green Rebels: Evaluating the Return Potential of Bayer, KWS Saat, and MustGrow Biologics
The global population continues to grow relentlessly, while the amount of arable land available per capita is shrinking. In this challenging environment, companies working on solutions to secure our food supply are taking center stage. But while the industry’s major players, such as Bayer or KWS Saat, grapple with regulatory hurdles and a rigid market landscape, innovative players like MustGrow Biologics could disrupt the field from behind. The key question for investors is no longer just who sells the most seeds, but increasingly who offers the smartest solutions for healthy soil. In this report, we examine the current situation at Bayer, where a major court ruling in the US is imminent. We also take a closer look at seed specialist KWS Saat, as well as a smaller but dynamic challenger, MustGrow, that could be on the verge of a technical breakout. All three stocks have the potential for exceptional performance. Read on to find out why the power of nature, in particular, could play a decisive role in the future—and may ultimately tip the scales.
Read
Commented by Armin Schulz on April 17th, 2026 | 07:30 CEST
Bayer, MustGrow Biologics, and Yara International: How to Capitalize on the 40% Fertilizer Price Surge in Your Portfolio
Since late February 2026, the war in Iran has blocked the Strait of Hormuz, sending nitrogen fertilizer prices soaring by 40%. While geopolitical shocks are disrupting supply chains, unusual opportunities are emerging for savvy investors. Analysts warn that the shortage of urea and other fertilizers will persist through the end of the year. But it is not just traditional manufacturers benefiting; smart alternative concepts are also stepping into the spotlight. Three completely different players in the agricultural sector could benefit disproportionately from the supply chaos: Bayer, MustGrow Biologics, and Yara International.
Read
Commented by Nico Popp on April 14th, 2026 | 07:15 CEST
Opportunities from the Agricultural Transition: Bayer, Sumitomo, and MustGrow Biologics
Conventional agriculture must rethink its approach: Chemical pesticides are to be reduced and replaced with biological alternatives. Strict regulations, such as the European Union's (EU) Farm-to-Fork Strategy, make this path irreversible and call for a 50% reduction in chemical risks associated with pesticides by 2030. While corporations like Bayer are restructuring their portfolios to be more environmentally friendly, global trading companies like Sumitomo are securing access to novel technologies. A key player in the agricultural transition is the innovative company MustGrow Biologics, which has developed natural plant protection products based on mustard seeds that effectively combat pests in the soil without causing long-term harm to the environment.
Read
Commented by Mario Hose on April 13th, 2026 | 07:30 CEST
100% Profit Potential in Sight: Vidac Pharma's Chance to Double vs Bayer and Evotec
Even in the spring of 2026, the stock market remains highly volatile. The upheavals caused by geopolitical crises have been and remain significant and ever-present. While heavyweights like Bayer are struggling to shake off their legal baggage and Evotec is steering into calmer waters, a stock from the back row is suddenly stepping into the spotlight. Vidac Pharma has also had a few turbulent months, and this is precisely where experienced investors now sense an opportunity. With a current share price of EUR 0.56, the company is poised for a potential recovery, an uptick, and perhaps even a complete revaluation. If the strategy pays off, the EUR 1 mark could be reached. That would be a chance to double their money for bold investors. But what is behind this optimism? In this report, we take a look at the industry giants and analyze not only them but also why, of all three, the one with the smallest market capitalization could develop the greatest momentum. It is about potential breakthroughs in cancer research and a management team that is optimizing many aspects for success.
Read